FDA Approves New Gene Therapy to Treat Rare Inherited Eye Disease
The FDA has approved a new gene therapy to help treat a rare inherited eye disease.
It’s called Voretigene Neparvovec, and it will be sold under the name Luxturna.
This is a one-time surgical treatment that will correct an inherited genetic mutation that can cause a certain type of blindness.
The new therapy is the third one to be approved for use in the U.S.; however, the developers say this is not a permanent fix. The treatment only lasts for about six years.